Summary
The pharmacokinetics of oral CdA (0.24 mg/kg) was studied in 4 patients (1 with hairy cell leukaemia and 3 with B-cell chronic lymphocytic leukaemia) to determine any effect of food and fasting with and without omeprazole.
Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting. The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake. Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C.V. 0.26 with and C.V. 0.27 without).
In conclusion, there was a small, though not statistically significant reduction in the bioavailability of CdA after food intake. Omeprazole did not significantly improve the bioavailability of CdA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kazimierczuk Z, Vilpo JA, Seela F (1993) Base-modified nucleosides related to 2-chloro-2′-deoxyadenosine. Helv Chim Acta (in press)
Plunkett, W, Saunders PP (1991) Metabolism and action of purine nucleoside analogs. Pharmacol Ther 49: 239–268
Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA (1985) Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75: 377–383
Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 322: 1117–1121
Saven A, Carrera CJ, Beutler E, Carson E, Prio LD (1991) 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia Lymphoma 5 [Suppl]: 133–138
Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Complete response to 2-chloro-deoxyadenosine (CdA) in B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 327: 1056–1061
Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD (1992) 2-chloro-deoxyadenosine treatment of lowgrade lymphomas. J Clin Oncol 10: 371–377
Santana VM, Mirro J Jr, Harwood FC, Kearns C, Schell MJ, Crom W, Blakley RL (1992) 2-chloro-deoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10: 363–370
Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in human. Cancer Res 51: 5570–5572
Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans; Alternative routes af administration. J Clin Oncol, 10: 1514–1518
Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Nat Acad Sci USA 89: 2970–2974
Kazimierczuk Z, Cottam HB, Ravankar GR et al. (1984) Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosine and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Chem Soc 106: 6379–6382
Beutler E (1992) Cladribine(2′-Chlorodeoxyadenosine). Lancet 340: 952–956
Liliemark J, Pettersson B, Juliusson G (1991) Determination of 2-chloro-2′-deoxyadenosine in human plasma. Biomedical Chromatogr 5: 262–264
Howeden CW, Forrest JAH, Ried JL (1984) Effect of single repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 24: 707–710
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Albertioni, F., Juliusson, G. & Liliemark, J. On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA). Eur J Clin Pharmacol 44, 579–582 (1993). https://doi.org/10.1007/BF02440863
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02440863